Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North ...
March 04 2021 - 7:47AM
Biogen Announces Plans to Build a New, State-of-the-Art Gene
Therapy Manufacturing Facility in Research Triangle Park, North
Carolina
Biogen Inc. (Nasdaq: BIIB) today announced its plans to build
a new gene therapy manufacturing facility at its Research Triangle
Park (RTP) manufacturing campuses in North Carolina to support its
growing gene therapy pipeline across multiple therapeutic areas.
As pioneers in neuroscience, Biogen is pursuing multiple
modalities with the aim of bringing life-saving medicines to those
who suffer from serious neurological and neurodegenerative
diseases. With this new facility, Biogen is investing in robust and
scalable gene therapy manufacturing with the goal of ensuring
reliable supply to patients worldwide. Gene therapy is an emerging
therapeutic modality that may be suitable for a growing list of
genetically validated targets in neuroscience.
“We plan to build differentiated, sustainable and advanced
manufacturing capabilities to support our gene therapy programs and
collaborations,” said Nicole Murphy, Senior Vice President, Global
Manufacturing and Technical Operations. “This additional investment
underscores our commitment to RTP and our mission to deliver a
reliable supply of high-quality medicines to the patients we serve.
We are poised with a diverse workforce that is passionate about
making a difference in the lives of patients and we look forward to
welcoming new colleagues from the community to join us in that
mission.”
Through the new facility, Biogen aims to continue its investment
in North Carolina and expand its existing operations and combined
workforce of approximately 1,900 employees at both campuses in RTP.
Biogen anticipates that the new facility will create approximately
90 new jobs, with an estimated total investment of approximately
$200 million. Biogen selected RTP for this new facility given the
region’s diverse pool of talent and the company’s 26-year track
record of attracting highly qualified and passionate employees in
North Carolina. Biogen’s priority is to continue to foster and
enable a diverse and inclusive workforce – representing age,
gender, sexual identity, race, ethnicity, Veterans, and people with
disabilities – that reflects the communities where we operate and
the patients who we serve.
The site will be 175,000 square feet and designed in compliance
with the most advanced sustainability standards regarding energy
use, waste management and water consumption.
About BiogenAt Biogen, our mission is clear: we
are pioneers in neuroscience. Biogen discovers, develops and
delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners
Walter Gilbert and Phillip Sharp. Today Biogen has the leading
portfolio of medicines to treat multiple sclerosis, has introduced
the first approved treatment for spinal muscular atrophy,
commercializes biosimilars of advanced biologics and is focused on
advancing research programs in multiple sclerosis and
neuroimmunology, Alzheimer’s disease and dementia, neuromuscular
disorders, movement disorders, ophthalmology, neuropsychiatry,
immunology, acute neurology and neuropathic pain.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social media –
Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe HarborThis news release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, relating to our plans to build a new gene
therapy manufacturing facility and the timing thereof; our
expectations regarding our multi-year investment in a new gene
therapy manufacturing facility; the anticipated benefits and
potential of a new gene therapy manufacturing facility; potential
of, and expectations for, our pipeline programs; our strategy and
plans; our capital allocation and investment strategy; and risks
and uncertainties associated with drug development and
commercialization. These forward-looking statements may be
identified by words such as “aim,” “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,”
“plan,” “possible,” “potential,” “will,” “would” and other words
and terms of similar meaning. You should not place undue reliance
on these statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including, without limitation, risks that the
construction of a new gene therapy manufacturing facility will be
completed in a timely manner or at all; uncertainty as to whether
the anticipated benefits of a new gene therapy manufacturing
facility can be achieved; the possibility that conditions to the
completion of the gene therapy manufacturing facility will not be
satisfied; risks of unexpected hurdles, costs or delays; failure to
obtain regulatory approvals; risks relating to investment in our
manufacturing capacity; problems with our manufacturing processes;
and the direct and indirect impacts of the ongoing COVID-19
pandemic on our business, results of operations and financial
condition. The foregoing sets forth many, but not all, of the
factors that could cause actual results to differ from our
expectations in any forward-looking statement. Investors should
consider this cautionary statement as well as the risk factors
identified in our most recent annual or quarterly report and in
other reports we have filed with the U.S. Securities and Exchange
Commission. These statements are based on our current beliefs and
expectations and speak only as of the date of this news release. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments or otherwise.
MEDIA
CONTACT: |
INVESTOR
CONTACT: |
David Caouette |
Mike Hencke |
Biogen Inc. |
Biogen Inc. |
Tel: (781) 464-3260 |
Tel: (781) 464-2442 |
Biogen (TG:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024